Bieche I, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud Yards: Quantitation regarding androgen receptor gene expression inside sporadic nipple cancers because of the real-big date RT-PCR: evidence you to MYC try an AR-managed gene. Carcinogenesis. 2001, 22 (9): 1521-1526. /carcin/twenty-two.9.1521.
Bratthauer GL, Lininger RA, Kid YG, Tavassoli FA: Androgen and you may the hormone estrogen receptor mRNA standing during the apocrine carcinomas. Diagn Mol Pathol. 2002, eleven (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical research away from apocrine breast sores. Uniform over-expression off androgen receptor followed closely by the increasing loss of the hormone estrogen and you can progesterone receptors from inside the apocrine metaplasia and you will apocrine carcinoma for the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Have always been J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S: Androgen receptors for the operable breast cancer: reference to most other steroid hormone receptors, correlations to prognostic things and you will predictive value to possess effectation of additive tamoxifen procedures. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Gather IB, Smoller B: Androgen receptors: good marker to increase susceptibility having identifying cancer of the breast in the body metastasis out-of unknown pri, 13 (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic pastime and you may clinical effects. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales A good, Skoog L, Chuan YC, Nordstedt G, Pousette A: Controls out of matrix metalloproteinase 13 expression of the androgen when you look at the prostate cancer tumors. Oncol Associate. 2004, 11 (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Research of prognostic requirement for androgen receptor term within the metastatic cancer of the breast. Virchows Arc. 2006, 449 (1): 24-31. /s00428-006-0213-six.
Parker RL, Hunter DG, Lesack DW, Cupples JB, Offer DR, Akbari M, Gilks CB: Review of interlaboratory type on immunohistochemical determination off the hormone estrogen receptor reputation playing with a cancer of the breast muscle microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases as well as their inhibitors when you look at the breast cancer. Br J Cancers. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica Yards, Suciu C, Cimpean A beneficial, Anghel A great: Immunohistochemical phrase from androgen receptor and you will prostate-specific antigen in the cancer of the breast. Folia Histochem Cytobiol. 2006, forty two (3): 165-172.
Egeblad M, Werb Z: The fresh new features to the matrix metalloproteinases from inside the cancers advancement. Nat Rev Malignant tumors. 2002, dos (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–on fundamental phase out-of cancers?. Cancer tumors Telephone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente Meters, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Age, Martinez Air-conditioning: The matrix metalloproteinase-9 controls the latest insulin-particularly development flirtymature recenze grounds-caused autocrine effect within the DU-145 carcinoma muscle. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Elizabeth, Matrisian LM, Mareel Yards: Launch of an intrusion supporter E-cadherin fragment from the matrilysin and you can stromelysin-step 1. J Telephone Sci. 2001, 114 (Pt 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] phrase chooses to possess cells with minimal susceptibility so you’re able to apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases in the angiogenesis: a relocation address to have therapeutic input. J Clin Dedicate. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius Los angeles, Nehring LC, Harding Elizabeth, Bolanowski Yards, Welgus HG, Kobayashi DK, Penetrate RA, Shapiro SD: Matrix metalloproteinases create angiostatin: effects to your neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: Complex jobs out of cells inhibitors from metalloproteinases inside disease. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.